Novacea Inc

Premium Company Profile

Publication Date	April 2008
Publisher	Datamonitor
Product Type	Report
Pages	39
ISBN Number	not applicable
Product Code	DAT11494

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

Novacea is a development stage biopharmaceutical company engaged in in-licensing, developing and commercializing of novel therapies for the treatment of diseases in the therapeutic area of oncology. The company's lead candidate, Ascenter, is a Phase III product candidate indicated for the treatment of androgen-independent prostate cancer (AIPC).

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Novacea's lead candidate, Ascenter, is a Phase III product candidate indicated for the treatment of androgen-independent prostate cancer (AIPC). Ascenter is also being studied in a Phase II study for the treatment of advanced pancreatic cancer. Novacea derives entire revenues from the grants contract that include revenues from grants associated with the company's two agreements with Aventis Pharmaceuticals. These grants consist of milestone payments earned related to the progress in two clinical trials involving Asentar and Aventis' Taxotere oncology product, sponsored by the company. Novacea's sole contributor to sales growth out to 2010 will be the license, collaboration and other revenues earned in connection with the development and commercialization of Asentar from Schering Plough. The company is expected to witness an absolute growth of +$57 million from collaboration revenues during the period 2006-2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content

Overview
Catalyst
Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&l
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- Ac Forecast Product Sales
- Competitors and Strategic Business Relationships
- Top Competitors
- Key Suppliers
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
- Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table of Figures
- Figure 1: Novacea - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table of Tables
- Table 1: Novacea - Key Facts
- Table 2: Novacea - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Novacea - Key Events Impacting Share Price Performance
- Table 4: Novacea - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: Novacea - Operating Cost Ratio Analysis, 2002-2006 (% of Total Revenues)
- Table 6: Novacea - Balance Sheet, 2002-2006 ($ Mn)
- Table 7: Novacea - Cash Flow, 2002-2006 ($ Mn)
- Table 8: Novacea - in-House Pipeline Products
- Table 9: Novacea - Forecast Sales, 2006-2010 ($ Mn)
- Table 10: Novacea - Top Competitors
- Table 11: Novacea - Key Suppliers
- Table 12: Novacea - Key Shareholders
- Table 13: Novacea - SWOT Analysis Summary
- Table 14: Novacea - Value Chain Analysis
- Table 15: Novacea - Key Employees
- Table 16: Novacea - Financial and Operational Overview